The company will also showcase its AI-powered platform designed to enhance the immunogenicity and clinical effectiveness of cancer vaccines.

CK Life Sciences is committed to advancing its research and development efforts to benefit cancer patients, with several vaccines currently in clinical and preclinical stages, including seviprotimut-L, which is in final research for treating stage IIB/IIC melanoma.

For those interested in the details of the presentations, full abstracts will be available in the AACR Online Itinerary Planner.

CK Life Sciences International, (Holdings) Inc. is set to present new preclinical study data on investigational cancer vaccines at the upcoming American Association for Cancer Research (AACR) Annual Meeting in Chicago, scheduled for April 25-30, 2025.

The AACR Annual Meeting is a significant event in the field of cancer research, attracting thousands of participants globally; the previous year's meeting saw 23,000 in-person attendees and 6,700 online participants from 78 countries.

At the meeting, CK Life Sciences will exhibit posters detailing cancer vaccines that target proteins associated with various cancers, including PRAME, PD-L1, B7-H3, and Claudin 6.

These proteins are linked to several types of cancer: PRAME is associated with melanoma, liver cancer, and leukemia; PD-L1 serves as an immune checkpoint that inhibits T cell activation; B7-H3 modulates T cell responses; and Claudin 6 is linked to breast, lung, and endometrial cancers.

Key poster presentations will include findings on PD-L1-PRAME dual vaccines, Claudin 6 vaccines for colon cancer, and the synergistic effects of PD-L1 and B7-H3 vaccines in pancreatic cancer, scheduled for April 27 and 28, 2025.

Melvin Toh, Vice President and Chief Scientific Officer of CK Life Sciences, expressed optimism regarding the preclinical efficacy of these vaccines and the advancements made with their AI platform.